Rubicon Research IPO Listing at 27.84% premium at ₹620 Per Share

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Thu Oct 16 2025

Rubicon Research IPO Listing at 27.84% premium at ₹620 Per Share

Click and Sign Up to Get Latest Updates on Rubicon Research Limited

Rubicon Research IPO Listing: The Rubicon Research IPO was subscribed 109.35 times at the close. In this subscription, qualified institutional buyers (QIBs) received 102.70 times the allocation, and non-institutional investors (NIIs) received 102.70 times the allocation. The retail quota of the issue was subscribed to 9.99%. Before delving deeper into the topic, go through the details of the Rubicon Research IPO.

Table of Contents

Rubicon Research IPO Listing

On the NSE, shares are listed at ₹620 per share, representing a 28.74% premium over the issue price of ₹485 per share. On the other hand, BSE platform shares are trading at ₹620.10, reflecting a 27.86% premium.

Rubicon Research IPO Details

It is a book-building IPO of ₹1,377.50 crores, comprising an entirely fresh issue of ₹1.03 crores. The problem will be listed on BSE and NSE on its tentative listing date, 16th October 2025. The Rubicon Research IPO date is scheduled for 9th October 2025 to 13th October 2025. The face value of Rubicon Research’s IPO shares is ₹1 per share, and the IPO price is set between ₹461 and ₹485 per share.

IPO Open Date	9th October 2025
IPO Close Date	13th October 2025
IPO Allotment Date	14th October 2025
Refund Initiation	15th October 2025
Issue Size	37,00,000 shares(aggregating up to ₹52.91 Cr)
Fresh Issue	1,03,09,762 share(aggregating up to ₹500.00 Cr)
Offer for Sale	1,80,92,762 shares of ₹1(aggregating up to ₹877.50 Cr)
Face Value	₹1 per share
Lot Size	30 shares
Issue Price Final	₹461 and ₹485 per share
Issue Type	Bookbuilding IPO
Listing At	BSE & NSE
Listing Date	16th October 2025

About Rubicon Research Limited

Rubicon Research Limited, established in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialised products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development. As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organisations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organisations.

Rubicon Research Limited Financials

The company’s financial analysis is essential before applying for the Rubicon Research IPO. Refer to the table to learn about Rubicon Research Limited’s financial information.

Year Ended	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	1,451.43	1,109.49	749.70
Revenue	1,296.22	872.39	419.00
Profit After Tax	134.36	91.01	-16.89
Net Worth	540.98	385.00	286.38
EBITDA	267.89	173.09	43.97
Reserve and Surplus	525.57	369.79	281.31
Total Borrowing	393.17	396.41	317.91

Explanation

Rubicon Research Limited’s revenue increased by 49% from ₹872.39 crore in March 2024 to ₹1,296.22 crore in March 2025. Moreover, the company’s PAT rose by 48% from ₹91.01 crores to ₹134.36 crores.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!